Chembio Diagnostics, Inc. (CEMI.QB) through its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures and markets proprietary point-of-care diagnostic tests, including rapid tests for HIV. Chembio’s proprietary rapid tests participate in the growing global demand for quick, accurate and cost effective screening and confirmation of infectious diseases.
Mr. Siebert has been Chairman of Chembio Diagnostic Systems, Inc. since 1992 and its President since mid-2002. Mr. Siebert’s background is in private equity and venture capital investing. From 1982 to 1991, he was associated with Stanwich Partners, Inc, which during that period financed and invested in middle market manufacturing and distribution companies. From 1992 to 1999, he was an investment consultant and business broker with Siebert Capital Corp. and Siebert Associates LLC, and was a principal investor in a privately held test and measurement company which was sold in 2002. Mr. Siebert received a JD from Case Western Reserve University School of Law in 1981 and a BA with Distinction in Economics from the University of Connecticut in 1978.
Richard J. Larkin, Chief Financial Officer
Mr. Larkin oversees Chembio’s financial activities and information systems. He has been Chief Financial Officer of Chembio Diagnostic Systems, Inc. since September 2003. Prior to joining Chembio Diagnostic Systems Inc., Mr. Larkin served as CFO at Visual Technology Group from May 2000 to September 2003. He led their consultancy program providing hands-on expertise in all aspects of financial service, including initial assessment of client financial reporting requirements within an Enterprise Resource Planning (Manufacturing) environment. Prior to joining VTG, he served as CFO at Protex International Corporation from May 1987 to January 2000. Mr. Larkin holds a BBA in Accounting from Dowling College and is a member of the American Institute of Certified Public Accountants.
Javan Esfandiari, Senior Vice President of Research & Development
Senior Vice President of Research & Development
In 1993 Mr. Esfandiari co-founded Sinovus Biotech AB, a Swedish biotech company where he served as Director of R&D for lateral flow technology until Chembio Diagnostic Systems, Inc. acquired Sinovus in 2000. From 1993 to 1997, Mr. Esfandiari was Director of R&D for On-Site Biotech, which was a joint venture between Sweden’s National Veterinary Institute and Sinovus. In this capacity Mr. Esfandiari was responsible for the development of rapid veterinary diagnostic tests. He has over 18 years’ experience in the diagnostic field during and over this period has developed more than 30 rapid point-of-care diagnostic products in the human and veterinary fields. He is the inventor of Chembio’s patented Dual Path Platform (DPP®) technology as well as several other diagnostic technologies patented in the US and globally. He has been the Principal or Co-Principal Investigator in research grants funded by the NIH, WHO, Gates and other national/international organizations and has co-authored over 30 publications on infectious diseases, immunology, vaccines and immunodiagnostic developments. Mr. Esfandiari received his B.Sc. in Clinical Chemistry and studied to M. Sc. Level in Molecular Biology from Lund University, Sweden.
Richard Bruce, VP, Operations
Mr. Bruce has been VP of Operations since April 2000. In this capacity, he directs Chembio’s production, maintenance, inventory, shipping and receiving, and warehouse operations. From 1998 to 2000, Mr. Bruce was a senior manager at V.I. Technologies. From 1993 to 1998, he held various management positions at Biomerieux. Mr. Bruce held director level positions at American Home Products from 1984 to 1993. Mr. Bruce has over 25 years of operations management experience with Fortune 500 in vitro diagnostic and blood fractionation companies. Mr. Bruce received his BS in Management from National Louis University in 1997.
Tom Ippolito, VP, Regulatory Affairs, QA & QC
Mr. Ippolito joined Chembio in June 2005. He has over 20 years experience with in vitro diagnostics for infectious diseases, protein therapeutics, vaccine development, Process Development, Regulatory Affairs and Quality Management. Over the years, Mr. Ippolito has held Vice President level positions at Biospecific Technologies, Corp., Director level positions in Quality Assurance, Quality Control, Process Development and Regulatory Affairs at United Biomedical, Inc. Mr. Ippolito is also the Course Director "drug development process" and "FDA regulations", a BioScience Certificate program at New York State University of Stony Brook.